Top FDA gene and cell therapy regulator to step down
Source ↗
👁 0
💬 0
Following Vijay Kumar’s exit, acting CBER Director Karim Mikhail will also oversee a review office that has become a battleground for debates on FDA flexibility.
Comments (0)